Maze Therapeutics, Inc. - Common Stock - par value $0.001 per share (MAZE) Institutional Ownership

13F Institutional Holders and Ownership History from Q1 2025 to Q4 2025

Type / Class
Equity / Common Stock - par value $0.001 per share
Symbol
MAZE on Nasdaq
Shares outstanding
48,247,400
Price per share
$45.00
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
48,364,392
Total reported value
$2,003,586,016
% of total 13F portfolios
0.02%
Share change
+4,657,492
Value change
+$199,192,055
Number of holders
142
Price from insider filings
$45.00
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Maze Therapeutics, Inc. - Common Stock - par value $0.001 per share (MAZE) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Third Rock Ventures IV, L.P. 9.3% -33% $179,808,372 -$64,304,000 4,473,958 -26% Third Rock Ventures IV, L.P. 31 Dec 2025
Frazier Life Sciences Public Fund, L.P. 9% +16% $174,515,671 +$39,762,017 4,342,266 +30% Frazier Life Sciences Public Fund, L.P. 31 Dec 2025
ARCH Venture Fund X, L.P. 9.4% $36,215,266 4,120,053 ARCH Venture Fund X, L.P. 31 Mar 2025
Deep Track Capital, LP 9% +30% $59,431,096 +$13,927,661 3,948,910 +31% Deep Track Capital, LP 30 Jun 2025
JANUS HENDERSON GROUP PLC 7.3% +22% $83,143,819 +$15,075,261 3,206,472 +22% JANUS HENDERSON GROUP PLC 30 Sep 2025
Matrix Capital Management Company, LP 3.5% -37% $42,880,026 -$21,586,725 1,653,684 -33% Matrix Capital Management Company, LP 30 Sep 2025
GV 2019, L.P. 2.9% -52% $57,528,994 -$42,419,680 1,388,583 -42% Alphabet Holdings LLC 31 Dec 2025
Foresite Capital Fund IV, L.P. 1.4% -70% $15,790,022 -$47,922,789 608,948 -75% James Tananbaum 30 Sep 2025

As of 31 Dec 2025, 142 institutional investors reported holding 48,364,392 shares of Maze Therapeutics, Inc. - Common Stock - par value $0.001 per share (MAZE). This represents 100% of the company’s total 48,247,400 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Maze Therapeutics, Inc. - Common Stock - par value $0.001 per share (MAZE) together control 84% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
Frazier Life Sciences Management, L.P. 9.5% 4,567,274 0% 5.1% $189,222,162
TRV GP IV, LLC 9.3% 4,473,958 -26% 73% $185,356,080
Deep Track Capital, LP 8.8% 4,246,440 +7.5% 4% $175,930,009
ARCH Venture Management, LLC 8.5% 4,120,053 0% 26% $170,693,796
JANUS HENDERSON GROUP PLC 6.5% 3,142,587 +318% 0.06% $130,197,379
BlackRock, Inc. 4.7% 2,287,155 +74% 0% $94,756,831
a16z Capital Management, L.L.C. 3.5% 1,702,225 0% 4.5% $70,523,182
VANGUARD GROUP INC 3.5% 1,697,015 +27% 0% $70,307,332
VR ADVISER, LLC 3.2% 1,548,569 +26% 3.2% $64,157,214
Alphabet Inc. 2.9% 1,388,583 -42% 2.2% $57,528,994
General Catalyst Group Management, LLC 2.1% 1,035,910 0% 19% $42,917,751
Woodline Partners LP 2.1% 1,035,229 0% 0.17% $42,889,537
TRV GP V, LLC 2% 950,800 0% 9.2% $39,391,644
Logos Global Management LP 2% 950,000 -23% 2.6% $39,358,500
Bellevue Group AG 1.8% 887,708 0.7% $36,777,742
MARSHALL WACE, LLP 1.8% 847,472 +9% 0.03% $35,110,765
ArrowMark Colorado Holdings LLC 1.6% 767,383 +41% 0.7% $31,792,678
Casdin Capital, LLC 1.6% 758,857 0% 2% $31,439,446
FMR LLC 1.5% 728,605 +11% 0% $30,186,105
Ikarian Capital, LLC 1.3% 644,680 -13% 3.5% $26,709,093
Caligan Partners LP 1.1% 550,191 2.1% $22,794,413
STATE STREET CORP 1.1% 533,005 +39% 0% $22,082,397
GEODE CAPITAL MANAGEMENT, LLC 1.1% 527,281 +11% 0% $21,850,329
Foresite Capital Management IV, LLC 1.1% 522,657 0% 9.4% $21,653,680
Squadron Capital Management LLC 1% 490,000 0% 9.1% $20,300,700

Institutional Holders of Maze Therapeutics, Inc. - Common Stock - par value $0.001 per share (MAZE) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 48,364,392 $2,003,586,016 +$199,192,055 $41.43 142
2025 Q3 42,970,633 $1,114,223,528 +$108,250,260 $25.93 93
2025 Q2 38,836,437 $476,719,891 -$14,337,293 $12.27 74
2025 Q1 40,038,674 $441,393,439 +$441,263,796 $11.01 68